Stock comparison
ARGENX SE is 7.9x more valuable than Immunovant, Inc. by market capitalization ($63.93 B vs $8.06 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
ARGX is larger
ARGENX SE is 7.9x more valuable than Immunovant, Inc. by market capitalization ($63.93 B vs $8.06 B).
Market value leader
ARGX
ARGENX SE is 7.9x more valuable than Immunovant, Inc. by market capitalization ($63.93 B vs $8.06 B).
| Metric | IMVT | ARGX |
|---|---|---|
| Market cap | $8.06 B | $63.93 B |
| US-listed rank | #1089 | #263 |
| Net income (latest FY) | -$505.61M | - |
| Net margin | - | - |
| P/E (trailing FY) | - | - |
| SEC filings | 611 | 272 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ARGENX SE is 7.9x more valuable than Immunovant, Inc. by market capitalization ($63.93 B vs $8.06 B).
Full pages: Immunovant, Inc. and ARGENX SE, or browse the full rankings.